State Street’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

State Street’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,235	Closed	-$14.4K	–	4417
2023 Q4	$14.4K	Buy	1,235 +432	+54%	+$5.79K	﹤0.01%	4369
2023 Q3	$12K	Hold	803	–	–	﹤0.01%	4495
2023 Q2	$16.7K	Hold	803	–	–	﹤0.01%	4611
2023 Q1	$7.23K	Hold	803	–	–	﹤0.01%	4758
2022 Q4	$8.59K	Hold	803	–	–	﹤0.01%	4815
2022 Q3	$11K	Hold	803	–	–	﹤0.01%	4889
2022 Q2	$29K	Buy	803 +123	+18%	+$7.44K	﹤0.01%	4827
2022 Q1	$68K	Buy	+680	New	+$90.4K	﹤0.01%	4737

Other funds holding EFTR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

State Street's EFTR Position: Q1 2024 in Review

State Street sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q1 2024, closing a stake of 1,235 shares — an estimated $14.4K sold.

State Street first reported a position in EFTR in Q1 2022 and held it in 8 quarters. The position peaked at $68K in Q1 2022. 17 funds tracked by Wall St. Rank hold EFTR as of Q1 2024.

State Street reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
State Street sold 1,235 eFFECTOR Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.4K.
State Street first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
State Street's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $68K in Q1 2022.
17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.